JP2004512305A - ドパミン作用性疾患状態を治療するための、ドパミンアゴニストを含有する経皮治療系と経口及び/または非経口調合剤との組合せ - Google Patents
ドパミン作用性疾患状態を治療するための、ドパミンアゴニストを含有する経皮治療系と経口及び/または非経口調合剤との組合せ Download PDFInfo
- Publication number
- JP2004512305A JP2004512305A JP2002537318A JP2002537318A JP2004512305A JP 2004512305 A JP2004512305 A JP 2004512305A JP 2002537318 A JP2002537318 A JP 2002537318A JP 2002537318 A JP2002537318 A JP 2002537318A JP 2004512305 A JP2004512305 A JP 2004512305A
- Authority
- JP
- Japan
- Prior art keywords
- tts
- use according
- dopamine agonist
- active ingredient
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10053397A DE10053397A1 (de) | 2000-10-20 | 2000-10-20 | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
PCT/EP2001/009826 WO2002034267A1 (de) | 2000-10-20 | 2001-08-24 | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004512305A true JP2004512305A (ja) | 2004-04-22 |
Family
ID=7661331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002537318A Pending JP2004512305A (ja) | 2000-10-20 | 2001-08-24 | ドパミン作用性疾患状態を治療するための、ドパミンアゴニストを含有する経皮治療系と経口及び/または非経口調合剤との組合せ |
Country Status (9)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018188420A (ja) * | 2017-04-28 | 2018-11-29 | 日東電工株式会社 | 経皮吸収型製剤 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
DE10226459A1 (de) * | 2002-06-13 | 2004-01-08 | Neurobiotec Gmbh | Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
WO2008001200A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
US20100035886A1 (en) * | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
AU2015201255B2 (en) * | 2008-01-14 | 2016-05-19 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
US20110229537A1 (en) * | 2010-03-17 | 2011-09-22 | Arbonne International Llc | Oral supplement |
CA2815959C (en) * | 2010-11-01 | 2020-10-06 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
BR112017015487A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo |
BR112019025420A2 (pt) | 2017-06-01 | 2020-06-16 | Xoc Pharmaceuticals, Inc. | Compostos policíclicos e usos destes |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US559782A (en) * | 1896-05-05 | Aaron mosley | ||
CH573936A5 (US07258871-20070821-C00002.png) * | 1971-08-05 | 1976-03-31 | Spofa Vereinigte Pharma Werke | |
DE2359128A1 (de) * | 1973-11-24 | 1975-06-12 | Schering Ag | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen |
US4166182A (en) * | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
US4202979A (en) | 1979-01-11 | 1980-05-13 | Eli Lilly And Company | 6-Ethyl(or allyl)-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
DE3063869D1 (en) * | 1979-06-13 | 1983-07-28 | Schering Ag | (ergolin-yl)-n', n'-diethyl urea derivatives, their preparation and pharmaceutical compositions containing them |
HU180467B (en) * | 1979-07-12 | 1983-03-28 | Gyogyszerkutato Intezet | Process for producing new ergol-8-ene- and ergoline-sceleted compounds |
US4742054A (en) * | 1982-11-23 | 1988-05-03 | Naftchi Nosrat E | Treatment of mammals suffering from damage to the central nervous system |
DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
US5364628A (en) * | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
DE3445784A1 (de) * | 1984-12-13 | 1986-06-26 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Verfahren zur herstellung von ergolin-derivaten |
IT1200603B (it) * | 1985-04-04 | 1989-01-27 | Poli Ind Chimica Spa | Composizione farmaceutiche ad attivita dopaminergica |
US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
US4800204A (en) * | 1987-05-07 | 1989-01-24 | Mueller Peter S | Method of controlling tobacco use |
US4798834A (en) * | 1987-08-31 | 1989-01-17 | Eli Lilly And Company | Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement |
US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
CA1336169C (en) * | 1988-03-01 | 1995-07-04 | Walther Birkmayer | Agent for treatment of parkinson's disease |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
US5252335A (en) * | 1989-07-12 | 1993-10-12 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
US5229129A (en) * | 1989-07-12 | 1993-07-20 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
US5114948A (en) * | 1989-10-19 | 1992-05-19 | Eli Lilly And Company | Stabilized pergolide compositions |
US5462744A (en) * | 1989-12-01 | 1995-10-31 | Boehringer Ingelheim Kg | Transdermal system for the administration of pharmacological compounds under pH-controlled conditions |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5063234A (en) * | 1990-05-25 | 1991-11-05 | Eli Lilly And Company | Method of inhibiting demineralization of bone |
US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
PT99864B (pt) | 1990-12-21 | 1999-06-30 | Schering Ag | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato |
US5371000A (en) * | 1991-02-08 | 1994-12-06 | Schering Aktiengesellschaft | Process for the production of ergoline derivatives |
DE4116912A1 (de) * | 1991-05-18 | 1992-11-26 | Schering Ag | Mittel zur transdermalen applikation enthaltend ergolin-derivate |
IT1252163B (it) * | 1991-12-03 | 1995-06-05 | Poli Ind Chimica Spa | Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica |
SE513429C2 (sv) | 1992-06-03 | 2000-09-11 | Syntello Inc | Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
CN1046723C (zh) * | 1993-04-06 | 1999-11-24 | 艾博特公司 | 四环化合物、含有它们的药物组合物及其用途 |
US5683711A (en) * | 1993-04-20 | 1997-11-04 | Hexal Pharma Gmbh | Active ingredient patch |
DE4313402A1 (de) | 1993-04-23 | 1994-10-27 | Hexal Pharma Gmbh | Transdermale Wirkstoffzubereitung |
US5674875A (en) | 1993-05-04 | 1997-10-07 | Eli Lilly And Company | Method of blocking human 5-hydroxytryptamine-2 receptors |
IL112106A0 (en) * | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
US5696125A (en) | 1995-02-24 | 1997-12-09 | Research Foundation Of The State University Of New York | Substance abuse-induced hemorrhagic stoke in an animal model |
US5643586A (en) * | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US5877183A (en) * | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
US6623752B1 (en) * | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
EP1006798A4 (en) | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES |
US6391871B1 (en) | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
DE19644998C1 (de) | 1996-10-30 | 1998-06-10 | Hanns Prof Dr Ludwig | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
US5849800A (en) * | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
GB9711043D0 (en) | 1997-05-29 | 1997-07-23 | Ciba Geigy Ag | Organic compounds |
US6114326A (en) | 1998-03-27 | 2000-09-05 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
DE19814083C2 (de) | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
EA200300125A1 (ru) | 1998-05-15 | 2003-06-26 | Фармация Энд Апджон Компани | Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
DE19821788C1 (de) | 1998-05-15 | 1999-12-02 | Sanol Arznei Schwarz Gmbh | Transdermales Therapeutisches System (TTS) Pergolid enthaltend |
US5994363A (en) | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
FR2786101B1 (fr) | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
IT1307934B1 (it) | 1999-01-27 | 2001-11-29 | Poli Ind Chimica Spa | Processo per la preparazione di derivati alchimercaptometilergolinici. |
MXPA01009658A (es) | 1999-03-26 | 2003-06-24 | Pozen Inc | Composiciones de dihidroergotamina de alta potencia. |
FR2792529B1 (fr) | 1999-04-26 | 2001-09-28 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
EE200100663A (et) | 1999-06-09 | 2003-04-15 | Chiesi Farmaceutici S.P.A. | Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks |
DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
WO2001032170A1 (en) | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
CZ295031B6 (cs) * | 1999-11-29 | 2005-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermální terapeutické systémy se zlepšenou stabilitou a způsob jejich výroby |
US20020110585A1 (en) | 1999-11-30 | 2002-08-15 | Godbey Kristin J. | Patch therapeutic agent delivery device having texturized backing |
US20020009486A1 (en) | 1999-11-30 | 2002-01-24 | 3M Innovative Properties Company | Therapeutic agent delivery incorporating reflective optical film |
US6613507B1 (en) | 2000-03-21 | 2003-09-02 | Yu-an Chang | Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications |
GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
IL152751A0 (en) * | 2000-05-12 | 2003-06-24 | Chiesi Farma Spa | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US6388079B1 (en) | 2000-08-29 | 2002-05-14 | Scinopharm Singapore Pte Ltd. | Process for preparing pergolide |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AR031152A1 (es) | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
US20020123503A1 (en) | 2000-12-21 | 2002-09-05 | Malcolm Ross | Cabergoline pharmaceutical compositions and methods of use thereof |
MXPA03006265A (es) | 2001-01-16 | 2004-06-25 | Purdue Research Foundation | Metodo de tratamiento de disfuncion relacionada con dopamina mediante administracion de un agonista de receptor de dopamina d1 completo, sin generacion de tolerancia. |
US7988991B2 (en) * | 2001-03-07 | 2011-08-02 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
US20040170672A1 (en) * | 2001-03-07 | 2004-09-02 | Thorsten Selzer | Transdermal therapeutic system for administration of partial dopamine-d2 agonists |
US6632217B2 (en) | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US6770638B2 (en) | 2001-04-20 | 2004-08-03 | Spectrum Pharmaceuticals, Inc. | Tetrahydroindolone and purine derivatives linked to arylpiperazines |
US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
ES2267627T3 (es) * | 2001-05-11 | 2007-03-16 | Jurgen K. Dr. Beck | Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal. |
US6500857B1 (en) | 2001-08-16 | 2002-12-31 | Nicholas V. Perricone | Subcutaneous muscle treatment using electronic stimulation and topical compositions |
US20020193758A1 (en) | 2001-06-18 | 2002-12-19 | Sca Hygiene Products Ab | Product |
US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
US20040120995A1 (en) * | 2002-04-01 | 2004-06-24 | Martin Debra A | Transdermal delivery of pergolide |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
CN100415217C (zh) * | 2002-12-19 | 2008-09-03 | 先灵公司 | 腺苷A2a受体拮抗剂的应用 |
MXPA05010450A (es) * | 2003-03-31 | 2005-11-04 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina. |
-
2000
- 2000-10-20 DE DE10053397A patent/DE10053397A1/de not_active Withdrawn
-
2001
- 2001-08-24 EP EP01976150A patent/EP1303278B1/de not_active Expired - Lifetime
- 2001-08-24 ES ES01976150T patent/ES2315309T3/es not_active Expired - Lifetime
- 2001-08-24 JP JP2002537318A patent/JP2004512305A/ja active Pending
- 2001-08-24 AU AU9551201A patent/AU9551201A/xx active Pending
- 2001-08-24 US US10/362,182 patent/US7258871B2/en not_active Expired - Fee Related
- 2001-08-24 AU AU2001295512A patent/AU2001295512B2/en not_active Ceased
- 2001-08-24 WO PCT/EP2001/009826 patent/WO2002034267A1/de active Application Filing
- 2001-08-24 DE DE50114474T patent/DE50114474D1/de not_active Expired - Lifetime
- 2001-08-24 AT AT01976150T patent/ATE413177T1/de not_active IP Right Cessation
- 2001-08-24 DK DK01976150T patent/DK1303278T3/da active
-
2005
- 2005-04-28 US US11/116,278 patent/US20050214353A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018188420A (ja) * | 2017-04-28 | 2018-11-29 | 日東電工株式会社 | 経皮吸収型製剤 |
US11179469B2 (en) | 2017-04-28 | 2021-11-23 | Nitto Denko Corporation | Transdermal absorption preparation |
Also Published As
Publication number | Publication date |
---|---|
ES2315309T3 (es) | 2009-04-01 |
DE50114474D1 (de) | 2008-12-18 |
DK1303278T3 (da) | 2009-02-09 |
ATE413177T1 (de) | 2008-11-15 |
DE10053397A1 (de) | 2002-05-02 |
US20040092544A1 (en) | 2004-05-13 |
US7258871B2 (en) | 2007-08-21 |
EP1303278B1 (de) | 2008-11-05 |
AU2001295512B2 (en) | 2006-09-21 |
WO2002034267A8 (de) | 2002-05-23 |
WO2002034267A1 (de) | 2002-05-02 |
AU9551201A (en) | 2002-05-06 |
EP1303278A1 (de) | 2003-04-23 |
US20050214353A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004512305A (ja) | ドパミン作用性疾患状態を治療するための、ドパミンアゴニストを含有する経皮治療系と経口及び/または非経口調合剤との組合せ | |
JP2004506682A (ja) | 経皮治療系 | |
KR100703101B1 (ko) | 부프레노르핀을 함유하는 서방성 진통제 | |
JP4316800B2 (ja) | メチルフェニデートで注意欠乏障害及び注意欠乏/活動亢進障害を治療する組成物及び方法 | |
JP4925823B2 (ja) | プラミペキソール活性剤を含む経皮治療システム | |
JP2010500992A (ja) | アルツハイマー病の経皮的治療法及び経皮的治療システム | |
NZ228467A (en) | Transdermal compositions containing deprenyl, i.e. n-methyl-n-(1-phenyl-2-propyl)-2-propinylamine | |
US20060105030A1 (en) | Transdermal therapeutic system | |
KR101307650B1 (ko) | 구역에 대한 경피 방법 및 패치 | |
CA2212874A1 (en) | Transdermal formulation | |
US5605701A (en) | Transdermal formulation | |
US20040219191A1 (en) | Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means | |
EP3522843B1 (en) | Pramipexole transdermal delivery system and uses thereof | |
JP2023539031A (ja) | エスケタミン懸濁tts | |
CA2502142A1 (en) | Transdermal therapeutic systems | |
TWI386191B (zh) | 用於嘔吐之經皮給藥方法及貼片 | |
TW201813634A (zh) | 普拉克索經皮貼片系統與用法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040826 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091104 |